I think we could see a doubling or slightly better on the prior corresponding period.
Wayne said in the webinar that ADAPT sales were 100% higher in The US for July of 2017 than July of 2016... The Saint spoke of a 'breakout' across the whole ADAPT range after his first month at Admedus.... Strong compounding growth for VascuCel and Neo.... And a few sales of CardioCel3D to the 10 'super clinics' which have been given the privilege of trialing it.
September quarter for 2016 was $1.6 million from memory, I'm calling $3.3 million in ADAPT sales for the September quarter of 2017.
If my figure is close to correct it is proof and confirmation that The ADAPT Tidal Wave has begun!
Ann: Annual Report to shareholders, page-58
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |